This article is more than 5 years old. Information may no longer be current.
Study: Preoperative glycemic control did not influence outcomes, hospital costs after TJA
Click Here to Manage Email Alerts
Among patients with type 2 diabetes who underwent total joint arthroplasty, investigators found preoperative glycemic control had no effect on patient-perceived outcomes during the medium term and length of stay, hospital costs and complication rates.
Researchers identified 120 consecutive primary total joint arthroplasties performed in patients with type 2 diabetes. Patients were followed for a mean of 5.9 years. Patients were placed into either an optimal preoperative glycemic control group or a suboptimal preoperative glycemic control group, which were determined by glycated hemoglobin serum levels. Preoperatively and at 6 weeks, 3 months, 6 months, 1 year and yearly postoperatively, investigators evaluated patients. The WOMAC, SF-36 and the Quality of Well Being Scale were used to assess patients’ quality of life and functional outcomes prior to and after surgery. Investigators also recorded length of stay, hospital costs and postoperative complication rates.
Patients in the optimal and suboptimal groups had improvements in all patient-reported outcomes. There were no significant differences regarding changes in measures between the groups. Investigators noted differences were not significant between the groups with regard to length of stay, hospital costs or short-term complication rates. – by Monica Jaramillo
Disclosure: Lavernia reports he is a paid consultant for Biomet, is a board or committee member of the Florida Orthopaedic Society, has stock or stock options in Johnson & Johnson, Stryker, Symmetry Medical (Telecomet), Wright Medical Technology Inc and Zimmer and has intellectual property with Mako Surgical/Stryker.
Click Here to Manage Email Alerts